Medical Devices

63 tickers in this theme
NewestHighest Score Ranks all matching reports in this category by score, highest first.
iRhythm Holdings, Inc.
IRTC·Healthcare
B ★★★Hold
Current$90.22
Target$123.44
Return+36.8%
Nov 8, 2026

iRhythm's differentiated cardiac monitoring platform offers long-term growth through expanding clinical adoption and improved operating leverage, but telemetry integration setbacks, regulatory exposure, and weak cash conversion threaten its recovery.

Score
66
Bausch + Lomb Corporation
BLCO·Healthcare
B ★★★Hold
Current$20.00
Target$21.24
Return+6.2%
Oct 31, 2026

Bausch + Lomb's established eye health franchise and improving premium product mix support earnings recovery, but substantial leverage, weak historical cash conversion and controlling-shareholder uncertainty limit investment upside.

Score
66
Knowles Corporation
KN·Technology
B ★★★Hold
Current$32.17
Target$35.70
Return+11.0%
Oct 26, 2026

Knowles benefits from rising demand for specialized defense, medical, and industrial electronic components, supported by strong orders and cash flow, but demanding valuation and manufacturing execution risks limit near-term upside.

Score
66
Novanta Inc.
NOVT·Technology
B ★★★Hold
Current$123.31
Target$129.00
Return+4.6%
Nov 12, 2026

Novanta benefits from specialized automation technology and expanding recurring medical revenue, but Riverpoint acquisition debt, future dilution, and demanding cash-flow growth expectations constrain near-term investment returns.

Score
65
Solventum Corporation
SOLV·Healthcare
B ★★★Hold
Current$90.38
Target$100.04
Return+10.7%
Nov 8, 2026

Solventum offers a credible medical technology turnaround supported by durable clinical franchises and portfolio simplification, but weak cash conversion, substantial leverage, and separation execution risks constrain near-term upside.

Score
65
Medline Inc.
MDLN·Healthcare
C ★★Sell
Current$39.64
Nov 7, 2026

Medline's integrated medical-surgical distribution network and strong organic growth provide durable expansion potential, but margin pressure, leverage, and a demanding valuation constrain its near-term investment appeal.

Score
64
Benchmark Electronics, Inc.
BHE·Technology
C ★★Sell
Current$68.37
Oct 31, 2026

Benchmark Electronics benefits from expanding semiconductor equipment and advanced computing demand, but its elevated historical valuation and thin manufacturing margins limit the margin of safety.

Score
63
Guardant Health, Inc.
GH·Healthcare
C ★★Sell
Current$150.87
Nov 8, 2026

Guardant Health could become a major beneficiary of expanding blood-based cancer screening and precision oncology, but its demanding valuation, persistent cash burn, and unproven operating leverage create substantial investment risk.

Score
62
LivaNova PLC
LIVN·Healthcare
C ★★Sell
Current$89.99
Nov 7, 2026

LivaNova benefits from durable cardiac-surgery and neurostimulation franchises with improving earnings and new-product potential, but demanding valuation and substantial legal liabilities constrain its risk-adjusted appeal.

Score
62
Bruker Corporation
BRKR·Healthcare
C ★★Sell
Current$61.31
Nov 7, 2026

Bruker's differentiated scientific instruments and recovering margins offer long-term growth potential, but weak organic demand, acquisition impairments, elevated leverage, and future preferred-share dilution constrain risk-adjusted returns.

Score
57